Vaccine adjuvants based on gamma inulin

Area of Science:

• Immunology
• Vaccinology
• Biochemistry

Background:

• Algammulin and gamma-inulin represent a novel class of vaccine adjuvants.
• Their mechanism involves activating the alternative pathway of complement (ACP).
• Inulin is registered for human use, and gamma-inulin is non-toxic and non-pyrogenic.

Purpose of the Study:

• To evaluate Algammulin and gamma-inulin as vaccine adjuvants.
• To assess their safety, efficacy, and mechanism of action.
• To explore their potential for commercial application in human and veterinary vaccines.

Main Methods:

• Research and development focused on understanding the biochemical basis of adjuvant action.
• Safety assessments including toxicity and pyrogenicity studies in various species.
• Formulation development, including the combination of alum with gamma-inulin (Algammulin).

Main Results:

• Algammulin and gamma-inulin are safe, non-toxic, and non-pyrogenic, with minimal systemic C3a production.
• Algammulin reduces adverse effects associated with alum, such as granuloma formation and IgE generation.
• These adjuvants potently enhance both Th1 and Th2 immune responses, boosting seroconversion, immunological memory, and cell-mediated immunity.

Conclusions:

• Gamma inulin-based adjuvants, particularly Algammulin, are safe, potent, and effective enhancers for vaccine responses.
• They offer a versatile platform for developing next-generation human and veterinary vaccines, especially those requiring robust cell-mediated defenses.
• Their well-understood mechanisms, stability, and cost-effectiveness make them attractive candidates for widespread use.